NCT02105454View on ClinicalTrials.gov

Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

May 23, 2014

Primary Completion Date

May 4, 2015

Study Completion Date

May 4, 2015

Conditions
Hepatitis C Virus
Interventions
DRUG

Grazoprevir (GZR)

100 mg oral tablet (total daily dose)

DRUG

Elbasvir (EBR)

10 mg oral capsule (total daily dose = 5 capsules)

DRUG

Ribavirin (RBV)

200 mg oral capsule (total daily dose = 4-7 capsules)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02105454 - Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048) | Biotech Hunter | Biotech Hunter